Bloomberg News

BiolineRx Jumps Most on Record After Deal With Genoscience

January 24, 2012

(Updates with closing share price in second paragraph)

Jan. 24 (Bloomberg) -- BioLineRx Ltd. surged the most on record after the Israeli company that develops therapeutic pharmaceutical drugs signed a deal with France’s Genoscience to develop and commercialize a treatment.

The shares surged 37 percent, the most since February 2007 when Bloomberg started tracking them, to 1.645 shekels at the 4:30 p.m. close in Tel Aviv.

BioLineRx signed an “exclusive license agreement” with Genoscience for its BL-8020 oral treatment for Hepatitis C, it said in a filing with the Tel Aviv Stock Exchange.

--Editors: Daliah Merzaban, Claudia Maedler

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus